The global Mechanical Thrombectomy Devices market size was accounted at USD 1.26 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 6.9% from 2022 to 2030. Mechanical thrombectomy devices consist of endovascular tools for removing clots from the blood vessels. These devices are available in different sizes and diameters, depending on the affected area. Mechanical thrombectomy is an advanced treatment option for ischemic stroke patients.
Multiple factors that drive the growth of the mechanical thrombectomy devices market are the increasing prevalence of stroke and cardiovascular diseases, rising life expectancy, procedural benefits offered by mechanical thrombectomy in cardiac surgeries, growing demand for minimally invasive surgeries, advancements in medical technologies, favorable government reimbursement policies, and the rising government expenditure for healthcare services. Furthermore, the growing FDA approvals are propelling the growth of the market. For instance, in December 2019, Vascular Medcure, Inc. received FDA clearance for its latest CAPERE Thrombectomy System, a mechanical device for treating deep vein thrombosis (DVT). The increasing prevalence of stroke worldwide leads to increased demand for efficient and innovative products, which is expected to drive the mechanical thrombectomy device market during the projected period. However, the strict regulatory policies and the lack of patient awareness about peripheral vascular diseases may restrain the market’s growth.
The mechanical thrombectomy devices market is classified based on the product type, application type, end-user, and region. The product type segment is categorized into coil retriever devices, stent retriever devices, aspiration devices, manual thrombectomy devices, and others (ultrasound-based devices). Stent retriever devices are projected to hold a significant market share in the coming years due to the surging demand for these devices. By application type, the market is divided into the stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), arteriovenous fistula (AVF), peripheral arterial disease (PAD), hemodialysis treatments, percutaneous coronary intervention (PCI), and others. The stroke segment is expected to lead the market during the forecast period. By end-user, the market is grouped into hospitals, ambulatory surgical centers, specialty clinics, and academic & research institutes. The hospitals segment is estimated to dominate this market over the forecast years due to the better reimbursement policies for hospital-based interventions and increasing demand for minimally invasive surgical procedures. Geographically, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America is anticipated to register a maximum share in the global mechanical thrombectomy devices market during the projected period. Factors such as the quick adoption of technically advanced products, increasing cardiac patients, growing demand for minimally invasive surgeries, availability of well-developed healthcare facilities, and rising healthcare expenditure contribute to the high market share.
Some of the key players operating in the mechanical thrombectomy devices market are Boston Scientific Corporation, Straub Medical AG, AngioDynamics, Acandis GmbH, NIPRO, Medtronic, MicroVention, Inc., Stryker Corporation, Phenox GmbH, Penumbra, Inc., Balt Extrusion, Medrad Inc. (Bayer HealthCare LLC), Johnson & Johnson, Rapid Medical Inc., and Anaconda Biomed SL, Imperative Care Inc., Vascular Medcure, Inc., and Others.
Global Mechanical Thrombectomy Devices Market, by Application Type, 2022-2030 (Value US$ Mn and Volume No. of Units)
